Chlamydia Lps Antibody (Tu-300)

Product Discontinued

Chlamydia Lps Antibody (Tu-300) Summary

• Immunogen: Made to Bacterial CHLAMYDIA LPS
• Specificity: This product is specific for Chlamydia lipopolysaccharide (LPS). LPS is a common feature of the outer envelope of gram negative bacteria, which acts as a potent endotoxin, triggering an innate immune response. Studies have shown however, that whilst the LPS of Chlamydia trachomatis does evoke an immune response, it displays only weak endotoxic activity when compared to that of other bacteria such as Salmonella minnesota or Neisseria gonorrhoeae. This antibody has not been cross-adsorbed and may react with LPS from related species.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/ Immunofluorescence
• Application Notes: Use in Immunocytochemistry/Immunofluorescence reported in scientific literature (PMID:32946535).

Reactivity Notes

Bacteria. Not yet tested in other species.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein A or G purified

Background

Chlamydia trachomatis is an intracellular organism. Chlamydia usually infects the cervix and fallopian tubes of women and the urethra of men. Chlamydial infections are believed to be one of the most common of all STDs. It is generally thought that in a population of 15 million, there are up to 300,000 cases of chlamydia each year. Thus, there are many undiagnosed cases of chlamydia in the community. It has been estimated that the true prevalence of chlamydia in the sexually active population may be in the order of 5% to 10%. Chlamydia is one of the leading causes of blindness in underdeveloped countries.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Chlamydia Lps Antibody (NB100-62450)(1)

Publication using NB100-62450

• Faris R, McCullough A, Andersen SE et al. The Chlamydia trachomatis secreted effector TmeA hijacks the N-WASP-ARP2/3 actin remodeling axis to facilitate cellular invasion PLoS pathogens 2020-09-01 [PMID: 32946535] (ICC/IF, Human)